ALKERMES | ALKS - Current Assets


ALKERMES reported $1.36B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
AbbVie USD 33.53B 4.47B Mar/2026
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
ALKERMES USD 1.36B 570.52M Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
Biogen USD 9.19B 216.3M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Coherus Biosciences USD 206.71M 254.25M Dec/2025
Eli Lilly USD 54.84B 794M Mar/2026
Gilead Sciences USD 18.64B 1.25B Mar/2026
Heron Therapeutics USD 228.98M 9.08M Mar/2026
Ionis Pharmaceuticals USD 2.94B 52M Mar/2026
J&J USD 59.17B 3.55B Mar/2026
Malin Corporation EUR 62.6M 26.7M Dec/2024
Merck USD 35.02B 8.5B Mar/2026
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Nektar Therapeutics USD 266.27M 15.09M Dec/2025
Neurocrine Biosciences USD 2.44B 86.6M Mar/2026
Otsuka Holdings JPY 1.6T 21.76B Mar/2026
Ovoca Bio EUR 1.56M 3.39M Jun/2025
Pfizer USD 42.82B 76M Mar/2026
Regeneron Pharmaceuticals USD 18.21B 187.3M Mar/2026
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026